ロード中...
The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which block the transition from the G1 to S phase of the cell cycle by interfering with Rb phosphorylation and E2F release, have shown potent antitumor activity and manageable toxicity in HR+/HER2− breast cancer patients. Some clinical trials involvin...
保存先:
| 出版年: | J Hematol Oncol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7195725/ https://ncbi.nlm.nih.gov/pubmed/32357912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00880-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|